BACKGROUND: @entity1289 ( @entity1289 ) inhibitors reduce urine protein excretion and slow the progression of @entity8 . The beneficial effect in slowing the progression of @entity8 is greater in @entity1 with higher urine protein excretion at the onset of treatment. We hypothesized that the greater beneficial effect of @entity1289 inhibitors on the progression of @entity8 in @entity1 with higher baseline levels of @entity644 is due to their greater antiproteinuric effect in these @entity1 . METHODS: Data were analyzed from 1860 @entity1 enrolled in 11 randomized controlled trials comparing the effect of antihypertensive regimens, including @entity1289 inhibitors to regimens not including @entity1289 inhibitors on the progression of @entity2316 . Multivariable linear regression analysis was used to assess the relationship between the level of @entity644 at baseline and changes in urine protein excretion during follow-up. The Cox proportional hazards analysis was used to assess the relationship between changes in urine protein excretion during follow-up and the effect of @entity1289 inhibitors on the time to doubling of baseline serum @entity1011 values or onset of @entity454 . RESULTS: Mean (median) baseline urine protein excretion was 1.8 (0.94) g/day. @entity1 with higher baseline urine protein excretion values had a greater reduction in @entity644 during the follow-up in association with treatment with @entity1289 inhibitors and in association with lowering @entity551 (interaction P < 0.001 for all). A higher level of urine protein excretion during follow-up (baseline minus change) was associated with a greater risk of progression [relative risk 5.56 (3.87 to 7.98) for each 1.0 g/day higher protein excretion]. After controlling for the current level of urine protein excretion, the beneficial effect of @entity1289 inhibitors remained significant [relative risk for @entity1289 inhibitors vs. control was 0.66 (0.52 to 0.83)], but there was no significant interaction between the beneficial effect of @entity1289 inhibitors and the baseline level of urine protein excretion. CONCLUSIONS: The antiproteinuric effects of @entity1289 inhibitors and lowering blood pressure are greater in @entity1 with a higher baseline urine protein excretion. The greater beneficial effect of @entity1289 inhibitors on @entity8 progression in @entity1 with higher baseline @entity644 can be explained by their greater antiproteinuric effects in these @entity1 . The current level of urine protein excretion is a modifiable risk factor for the progression of @entity2316 . @entity1289 inhibitors provide greater beneficial effect at all levels of current urine protein excretion.

@entity644 as a modifiable risk factor for the progression of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal disease'] @entity1289 :: ('1636', 'Gene') :: ['ACE', 'Angiotensin-converting enzyme'] @entity2316 :: ('MESH:D003928', 'Disease') :: ['non-diabetic renal disease'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity551 :: ('MESH:D007022', 'Disease') :: ['systolic and diastolic blood pressures'] @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease']
@entity2316 :: (MESH:D003928,Disease) :: ['non-diabetic renal disease']
